The company will get up to $1.2 billion from the US Department of Health and Human Services to speed the development and production of the vaccine with the goal of delivering the first doses as early as October, according to officials.
Some 36 percent of respondents said they would be less willing to take a vaccine if US President Donald Trump said it was safe, compared with only 14 percent who would be more interested.
A person being injected as part of the first human trials in the United Kingdom to test a potential CCP virus vaccine, at Oxford University, England, on April 23, 2020. There are now no approved treatments or vaccines for Covid-19, which are being tested by pharmaceutical firms across the world.
"Our study provided a new vaccine platform simulating coronavirus surface protein and internal nucleic acids, therefore, combining features of inactivated vaccines and mRNA vaccines", the researchers added. Mr. Trump said last week Operation Warp Speed aims to make millions of doses of a vaccine available by the end of 2020.
Coronavirus: Potential virus vaccine 'ready for September'
Drug maker AstraZeneca said Thursday it had secured its first agreements for 400 million doses of a COVID-19 vaccine it is testing, bolstered by an investment from the US vaccine agency.
"The company added it was "engaging with worldwide organisations", including the World Health Organization, for the fair allocation and distribution of the vaccine around the world". Relating it to taking "multiple shots on goal", Fauci said it not only increases the chances that at least one will be successful, but is also good for "global availability".
The vaccine was developed by Oxford University's Jenner Institute, working with the Oxford Vaccine Group.
However, AstraZeneca stressed that the vaccine may not work and that it was still waiting for results from an early-stage trial in southern England, before any moves towards late-stage testing.More news: Xiaomi's MIUI 12 is Coming to These Devices: Check All the Details
Among those who expressed little or no interest in taking a vaccine, almost half said that they were anxious about the speed in which one is being developed - with more than 40% believing that the vaccine may be riskier than the disease itself.
Soriot said the company was grateful for the "substantial support" from the United Kingdom and USA governments to accelerate the development and production of the vaccine.
"We need to defeat the virus together or it will continue to inflict huge personal suffering and leave long-lasting economic and social scars in every country around the world", he said.
"We are so proud to be collaborating with Oxford University to turn their ground-breaking work into a medicine that can be produced on a global scale".More news: Rep. Johnson announces $16 billion relief program available to La. farmers, ranchers
Although billed as one of the best hopes of creating an effective antidote to coronavirus, initial trials of the vaccine, known as AZD1222, have had mixed results.
"Expenses to progress the vaccine are anticipated to be offset by funding by governments", the company said.More news: Ahmaud Arbery shooting: 3rd man arrested and charged with murder